BioSenic SA
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
BIOS | BR
Overview
Corporate Details
- ISIN(s):
- BE0970179827 (+1 more)
- LEI:
- 549300HFIIMTOP1DFR76
- Country:
- Belgium
- Address:
- RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
- Website:
- http://www.biosenic.com/
Description
BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-23 07:00 |
BOTHE_PR_2022-03-23_Transparency Notification_Nyenburgh_FR_Final.pdf
|
French | PDF • 233.3 KB | ||
| 2022-01-19 07:00 |
Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook
|
English | PDF • 249.2 KB | ||
| 2022-01-19 07:00 |
Bone Therapeutics fait le point sur ses activités au quatrième trimestre 2021 e…
|
French | PDF • 264.7 KB | ||
| 2021-12-23 07:00 |
Notiication de transparence au 07.12.2021.pdf
|
French | PDF • 1.7 MB | ||
| 2021-12-23 07:00 |
BOTHE_PR_2021-12-23_Transparency Notification_SRIW_EN_Final.pdf
|
English | PDF • 233.7 KB | ||
| 2021-12-23 07:00 |
BOTHE_PR_2021-12-23_Transparency Notification_SRIW_FR_Final.pdf
|
French | PDF • 246.3 KB | ||
| 2021-12-10 07:00 |
20211208 Melding FSMA_Nyenburgh Holding BV_revised_signed.pdf
|
Dutch | PDF • 438.2 KB | ||
| 2021-12-10 07:00 |
BOTHE_PR_2021-12-10_Transparency Notification_Nyenburgh_EN_Final.pdf
|
English | PDF • 222.5 KB | ||
| 2021-12-10 07:00 |
BOTHE_PR_2021-12-10_Transparency Notification_Nyenburgh_FR_Final.pdf
|
French | PDF • 236.3 KB | ||
| 2021-12-09 07:00 |
BOTHE_PR_2021-12-09_Private placement_Denominator_EN_Final.pdf
|
English | PDF • 221.8 KB | ||
| 2021-12-09 07:00 |
BOTHE_PR_2021-12-09_Private placement_Denominator_FR_Final.pdf
|
French | PDF • 235.3 KB | ||
| 2021-12-03 14:00 |
BoneTherapeutics_2021-12-02_Special Report BoD_Capital increase_FR_Final.pdf
|
French | PDF • 207.3 KB | ||
| 2021-12-03 07:00 |
Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement
|
English | PDF • 281.0 KB | ||
| 2021-12-03 07:00 |
Bone Therapeutics lève avec succès 3,3 millions d’euros dans le cadre d’un plac…
|
French | PDF • 298.5 KB | ||
| 2021-11-29 07:00 |
Bone Therapeutics and Link Health sign a non-binding term sheet for the global …
|
English | PDF • 314.9 KB |
Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioSenic SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioSenic SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-16 | Rieger Francois | Board | Sell | 2,500,000 | 25,000.00 EUR |
| 2024-08-06 | Rieger Francois | Board | Sell | 868,653 | 7,186.87 EUR |
| 2024-08-05 | POMI SCHNEITER VERONIQUE | Board | Sell | 534,750 | 4,331.47 EUR |
| 2024-08-02 | POMI SCHNEITER VERONIQUE | Board | Sell | 193,900 | 1,609.37 EUR |
| 2024-08-01 | Rieger Francois | Board | Sell | 1,236,684 | 11,463.87 EUR |
| 2024-08-01 | POMI SCHNEITER VERONIQUE | Board | Sell | 140,003 | 1,246.03 EUR |
| 2024-07-31 | POMI SCHNEITER VERONIQUE | Board | Sell | 503,771 | 4,685.07 EUR |
| 2024-07-30 | POMI SCHNEITER VERONIQUE | Board | Sell | 360,021 | 3,348.20 EUR |
| 2024-07-29 | POMI SCHNEITER VERONIQUE | Board | Sell | 372,893 | 3,430.62 EUR |
| 2024-07-24 | POMI SCHNEITER VERONIQUE | Board | Sell | 2,168,361 | 21,033.10 EUR |
Peer Companies
